OKYO News and Press, OKYO Pharma Limited From 09/08/23

Full enrollment achieved on September 6 th with a total of 240 patients enrolled in study Top-line data planned for release in December 2023 Phase 2 trial is designed as a potential registration trial, with pre-specified primary efficacy endpoints covering both a sign ...

2023-08-31 12:41:47 ET Gainers: Acer Therapeutics ( ACER ) +133% . Prime Number Acquisition I Corp. ( NCNC ) +41% . Minim ( MINM ) +29% . Canopy Growth Corporation ( CGC ) +26% . Upland Software ( UPLD ) +23% . Hydrofarm Hold...

2023-08-31 10:00:40 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) Tech Ruled The First Half Of 2023, The Industry You Need To Watch In The Second Half XLV Vs. VHT: A Head-To-Head Healthcare ETF C...

2023-08-31 08:17:07 ET Dollar General DG -16% after Q2 release . OKYO Pharma ( OKYO ) -14% . Top KingWin ( TCJH ) -10% . ReTo Eco-Solutions ( RETO ) -11% . Beneficient ( BENF ) -10% . Digital Brands Group ( DBGI ) -9% . ...

2023-08-30 13:16:02 ET Gainers: NanoVibronix ( NAOV ) +127% . iCoreConnect ( ICCT ) +49% . Aravive ( ARAV ) +35% . AEON Biopharma ( AEON ) +33% . Alarum Technologies ( ALAR ) +25% . Greenland Technologies Holding Corporation ...

Full enrollment anticipated by first week of September OKYO on schedule to release top-line data before end of 2023 Phase 2 trial is designed as potential registration trial with pre-specified primary efficacy endpoints covering both a sign and symptom of DED LONDON and ...

2023-08-29 10:25:57 ET Are you trading penny stocks this week? Chances are that if you’re reading this article, you have some intention of finding more info on cheap stocks. Thanks to the heightened level of volatility in the stock market today, traders, in particular, have turne...

2023-08-29 07:59:26 ET More on OKYO Pharma OKYO Pharma rebounds on withdrawal of equity offering Seeking Alpha’s Quant Rating on OKYO Pharma Earnings data for OKYO Pharma For further details see: OKYO Pharma regains Nasdaq compliance

NEW YORK and LONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dolla...

LONDON and NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”) to address the significant unmet need in this multi-billion-dollar market, today...